Loading...

© 2026 MedXY

Contact us About us Privacy Policy MedXY story

MedXY News - aortic stenosis

MedXY AI/MedXY News/Tag: aortic stenosis

MedXY News

EnglishTag

aortic stenosis

20 · 20 / page

Ask MedXY AI

type 2 diabetes clinical trial heart failure immunotherapy obesity atrial fibrillation cardiovascular risk Cardiology biomarkers clinical trials Hypertension oncology critical care public health artificial intelligence Alzheimer's disease breast cancer diabetes cardiovascular disease type 1 diabetes nutrition chronic kidney disease

Latest news

Tag

10-Year Randomized Outcomes of Transcatheter or Surgical Aortic Valve Replacement in Intermediate-Risk Aortic Stenosis: What PARTNER 2A Adds to the Long-Term TAVR Evidence Base

Cardiologyaortic stenosislong-term outcomes

10-Year Randomized Outcomes of Transcatheter or Surgical Aortic Valve Replacement in Intermediate-Risk Aortic Stenosis: What PARTNER 2A Adds to the Long-Term TAVR Evidence Base

By MedXY|Jun 17, 2026

The PARTNER 2A 10-year data show higher mortality and reintervention with balloon-expandable SAPIEN XT TAVR versus surgery in intermediate-risk patients, driven mainly by transthoracic access. Contemporary 10-year SAPIEN 3 data, however, su

Myocardial Fibrosis Predicts Outcomes in Asymptomatic Severe Aortic Stenosis, But Early Valve Replacement May Not Offer Universal Benefit

aortic stenosis

Cardiac Magnetic Resonance

Myocardial Fibrosis Predicts Outcomes in Asymptomatic Severe Aortic Stenosis, But Early Valve Replacement May Not Offer Universal Benefit

By MedXY|Apr 17, 2026

The EVOLVED trial reveals that higher myocardial fibrosis burden associates with adverse events in asymptomatic severe aortic stenosis patients, yet early intervention benefits appear nuanced—showing promise for reducing hospitalizations in

TAVI Superiority in Women with Aortic Stenosis: New Evidence from the DEDICATE-DZHK6 Trial

Cardiologyaortic stenosisSAVR

TAVI Superiority in Women with Aortic Stenosis: New Evidence from the DEDICATE-DZHK6 Trial

By MedXY|Mar 17, 2026

A subgroup analysis of the DEDICATE-DZHK6 trial reveals that TAVI significantly reduces the 1-year risk of death or stroke compared to SAVR in both sexes, with particularly pronounced clinical benefits for women, especially regarding stroke

Moderate Mixed Aortic Valve Disease: Why Moderate Severity Carries Severe Risk

Cardiologyaortic stenosisCardiology

Moderate Mixed Aortic Valve Disease: Why Moderate Severity Carries Severe Risk

By MedXY|Mar 14, 2026

A large-scale multicenter study demonstrates that moderate mixed aortic valve disease (MAVD) carries a mortality risk comparable to severe aortic stenosis when symptoms or left ventricular dysfunction are present, challenging current guidel

Beyond the Gradient: Invasive Exercise Hemodynamics Confirm Discordant Low-Gradient Aortic Stenosis as a High-Risk Phenotype

Cardiologyaortic stenosisCardiology

Beyond the Gradient: Invasive Exercise Hemodynamics Confirm Discordant Low-Gradient Aortic Stenosis as a High-Risk Phenotype

By MedXY|Mar 9, 2026

A pivotal study using invasive exercise hemodynamics reveals that discordant low-gradient aortic stenosis behaves similarly to high-gradient severe disease, often masking underlying heart failure with preserved ejection fraction (HFpEF) phy

The Hemodynamic Paradox of Valve-in-Valve TAVR: Redefining ‘Optimal’ Gradients and Patient-Prosthesis Mismatch

Cardiologyaortic stenosisheart failure

The Hemodynamic Paradox of Valve-in-Valve TAVR: Redefining ‘Optimal’ Gradients and Patient-Prosthesis Mismatch

By MedXY|Mar 2, 2026

This review analyzes new registry data revealing that low discharge gradients (<10 mm Hg) after balloon-expandable ViV-TAVR correlate with reduced LVEF and higher 5-year mortality, challenging conventional hemodynamic success metrics.

TAVR vs. Surgery in Low-Risk Patients: 7-Year PARTNER 3 Results Confirm Long-Term Parity

Cardiologyaortic stenosisPARTNER 3

TAVR vs. Surgery in Low-Risk Patients: 7-Year PARTNER 3 Results Confirm Long-Term Parity

By MedXY|Feb 22, 2026

Seven-year data from the PARTNER 3 trial demonstrate that TAVR remains noninferior to surgical aortic-valve replacement in low-risk patients, with comparable rates of death, stroke, and valve durability, supporting TAVR as a sustained alter

Rethinking Hemodynamics in Aortic Stenosis: The Paradoxical Normal-Flow, Low-Ejection Fraction Phenotype and Post-TAVI Outcomes

Cardiologyaortic stenosishemodynamics

Rethinking Hemodynamics in Aortic Stenosis: The Paradoxical Normal-Flow, Low-Ejection Fraction Phenotype and Post-TAVI Outcomes

By MedXY|Jan 22, 2026

A substudy of the COMPARE-TAVI 1 trial identifies a unique NF-LEF phenotype in 10.7% of aortic stenosis patients. Despite reduced LVEF, these patients maintain normal flow through eccentric remodeling and achieve clinical improvements post-

TAVI vs. SAVR in Women: RHEIA Trial Reveals Distinctive Echocardiographic Advantages for Both Approaches

Cardiologyaortic stenosisSAVR

TAVI vs. SAVR in Women: RHEIA Trial Reveals Distinctive Echocardiographic Advantages for Both Approaches

By MedXY|Jan 22, 2026

The RHEIA trial substudy compares echocardiographic outcomes between TAVI and SAVR in women. While SAVR offers superior LVH regression and lower gradients, TAVI demonstrates significant benefits in preserving right ventricular function and

Myval THV Demonstrates 1-Year Noninferiority to Established Transcatheter Heart Valves: Insights from the LANDMARK Trial

Cardiologyaortic stenosisLANDMARK Trial

Myval THV Demonstrates 1-Year Noninferiority to Established Transcatheter Heart Valves: Insights from the LANDMARK Trial

By MedXY|Dec 25, 2025

The LANDMARK trial reports that the novel Myval balloon-expandable transcatheter heart valve is clinically noninferior to contemporary SAPIEN and Evolut series at one year, offering comparable safety, hemodynamic performance, and quality-of

Surgical Aortic Valve Replacement Emits Twice the CO2 of TAVR: What This Means for Practice and Policy

Cardiologyaortic stenosisSAVR

Surgical Aortic Valve Replacement Emits Twice the CO2 of TAVR: What This Means for Practice and Policy

By MedXY|Nov 29, 2025

A life cycle assessment found SAVR produces roughly double the carbon footprint of transcatheter aortic valve replacement (TAVR), with postoperative ICU and ward care as the main drivers. Results highlight opportunities to decarbonize cardi

Dual Pathology No Longer a Dead End: Tafamidis and AVR Improve Survival in Aortic Stenosis with Cardiac Transthyretin Amyloidosis

Cardiologyaortic stenosisAVR

Dual Pathology No Longer a Dead End: Tafamidis and AVR Improve Survival in Aortic Stenosis with Cardiac Transthyretin Amyloidosis

By MedXY|Nov 29, 2025

In a multinational registry of patients with concomitant aortic stenosis (AS) and transthyretin cardiac amyloidosis (ATTR‑CA), both ATTR‑specific therapy (predominantly tafamidis) and aortic valve replacement (AVR) were independently associ

Seven-Year Outcomes of TAVR vs. Surgical Aortic Valve Replacement in Low-Risk Patients: Insights from PARTNER 3

Cardiologyaortic stenosislong-term outcomes

Seven-Year Outcomes of TAVR vs. Surgical Aortic Valve Replacement in Low-Risk Patients: Insights from PARTNER 3

By MedXY|Oct 31, 2025

At 7 years, transcatheter and surgical aortic valve replacement show comparable outcomes including survival, stroke, and valve durability among low-risk patients with severe aortic stenosis, affirming TAVR’s long-term efficacy.

Head-to-Head Comparison of SAPIEN 3 and Myval Transcatheter Heart Valves in TAVI: Insights from the COMPARE-TAVI 1 Trial

Cardiologyaortic stenosisCOMPARE-TAVI

Head-to-Head Comparison of SAPIEN 3 and Myval Transcatheter Heart Valves in TAVI: Insights from the COMPARE-TAVI 1 Trial

By MedXY|Oct 6, 2025

The COMPARE-TAVI 1 trial demonstrates non-inferiority of Myval transcatheter heart valves compared to SAPIEN 3 THVs at 1-year post-TAVI for a composite clinical endpoint in severe aortic stenosis patients.

Three-Year Outcomes of NOTION-2 Trial: Comparing TAVR and SAVR in Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis

Cardiologyaortic stenosisSAVR

Three-Year Outcomes of NOTION-2 Trial: Comparing TAVR and SAVR in Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis

By MedXY|Oct 6, 2025

The NOTION-2 trial demonstrates comparable three-year outcomes between TAVR and SAVR in low-risk patients aged 60-75 with severe tricuspid or bicuspid aortic stenosis, with low rates of valve deterioration and re-intervention.

TAVI vs SAVR at Low–Intermediate Risk: What the New Individual‑Patient Meta‑Analysis Means for Practice

Cardiologyaortic stenosisMeta-Analysis

TAVI vs SAVR at Low–Intermediate Risk: What the New Individual‑Patient Meta‑Analysis Means for Practice

By MedXY|Oct 5, 2025

A patient‑level meta‑analysis of randomized trials finds transcatheter aortic valve implantation (TAVI) reduces 1‑year risk of death or stroke versus surgical AVR in low– to intermediate‑risk patients—informing patient selection, heart‑team

Valve Underexpansion in ACURATE neo2 TAVR: Implications for Clinical Outcomes and Future Directions

CardiologyACURATE neo2aortic stenosis

Valve Underexpansion in ACURATE neo2 TAVR: Implications for Clinical Outcomes and Future Directions

By MedXY|Oct 3, 2025

Underexpansion of the ACURATE neo2 valve during TAVR is linked to increased risk of death, stroke, and rehospitalization at one year, suggesting that achieving optimal valve expansion may improve patient outcomes.

Electronic Provider Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis

Cardiologyaortic stenosisaortic valve replacement

Electronic Provider Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis

By MedXY|Oct 3, 2025

This study evaluates the efficacy of electronic provider notifications in increasing aortic valve replacement rates for severe aortic stenosis, improving outcomes in patients.

Early TAVR Benefits in Asymptomatic Severe Aortic Stenosis: Insights from Cardiac Biomarker Analysis in the EARLY TAVR Trial

Cardiologyaortic stenosishs-cTnT

Early TAVR Benefits in Asymptomatic Severe Aortic Stenosis: Insights from Cardiac Biomarker Analysis in the EARLY TAVR Trial

By MedXY|Oct 3, 2025

Cardiac biomarkers NT-proBNP and hs-cTnT predict higher risk in asymptomatic severe aortic stenosis, but early TAVR benefits patients regardless of biomarker levels, with greater relative advantage seen in those with lower biomarker concent

Percutaneous versus Surgical Approaches in Aortic Stenosis with Complex Coronary Disease: TCW Trial Insights

Cardiologyaortic stenosisCABG

Percutaneous versus Surgical Approaches in Aortic Stenosis with Complex Coronary Disease: TCW Trial Insights

By MedXY|Oct 1, 2025

The TCW trial demonstrates that FFR-guided PCI plus TAVI is non-inferior and even superior to SAVR plus CABG in elderly patients with severe aortic stenosis and complex coronary artery disease.

Ask MedXY AI

Most popular

New A-TANGO Organ Failure Score Refines ACLF Diagnosis and Risk Stratification in Global Cohorts

MIND Diet Linked to Lower Cancer Risk and Reduced Mortality, With New Genetic Insights

High-Intensity Resistance Training Improves Lower Limb Strength More Than Low-Moderate Intensity in Older Adults

Clinical Updates

Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction

Family Medicine & Nutrition

The Curious Scent of Feces: The Dual Identity and Health Secrets of Skatole